Driehaus Capital Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Driehaus Capital Management’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-32,122	Closed	-$2.98M	–	632
2014 Q4	$2.98M	Buy	32,122 +16,436	+105%	+$1.3M	0.12%	229
2014 Q3	$1.08M	Sell	15,686 -16,512	-51%	-$1.18M	0.04%	421
2014 Q2	$3.37M	Buy	32,198 +7,806	+32%	+$664K	0.11%	252
2014 Q1	$2.02M	Buy	+24,392	New	+$2.26M	0.06%	333
2013 Q4	–	Sell	-25,060	Closed	-$1.59M	–	582
2013 Q3	$1.59M	Sell	25,060 -123,351	-83%	-$6.07M	0.06%	304
2013 Q2	$6.23M	Buy	+148,411	New	+$6.76M	0.27%	123

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Driehaus Capital Management's GEVA Position: Q1 2015 in Review

Driehaus Capital Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 32,122 shares — an estimated $2.98M sold.

Driehaus Capital Management first reported a position in GEVA in Q2 2013 and held it in 6 quarters. The position peaked at $6.23M in Q2 2013. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

Driehaus Capital Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
Driehaus Capital Management sold 32,122 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $2.98M.
Driehaus Capital Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 6 quarters.
Driehaus Capital Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $6.23M in Q2 2013.
130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Driehaus Capital Management's 13F filing for Q1 2015, filed 15 May 2015.